OTC:SLNCF | Free Cash Flow | Silence Therapeutics plc

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2022-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$15.6M$0.00-$15.6M
2025-12-31-$17.29M$0.00-$17.29M
2025-03-31-$12.31M$4,000.00-$12.31M
2024-12-31-$27.48M$62,000.00-$27.54M-223.89%
2024-03-31-$9.14M$0.00-$9.14M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$62.27M$55,000.00-$62.33M
2024-12-31-$67.64M$211,000.00-$67.85M
2023-12-31-$49.46M$56,000.00-$49.52M
2022-12-31-$57.04M$173,000.00-$57.22M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.